StockGuide AI - assistente para pesquisa de mercado

Analistas da Carter Worth recomendam a compra de ações da Incyte (INCY) à medida que rompe uma faixa de sete meses

06/26/2026, 11:37 AM investing recommendation Analysts: analysts, Carter Worth biotech

A Incyte, uma empresa biofarmacêutica, está prestes a uma possível ruptura após um período de estagnação de sete meses, com analistas sugerindo uma perspectiva otimista ao tentar superar a marca de $125.

Analistas do UBS reduziram a meta de preço da Zealand Pharma (ZEAL) para 540 coroas dinamarquesas devido a preocupações com a tolerabilidade do survodutide

06/18/2026, 10:36 PM business rating_drop Analysts: analysts, UBS biotech

As ações da Zealand Pharma enfrentaram quedas significativas após dados decepcionantes sobre seu medicamento para perda de peso, survodutide, levando os analistas a reduzir as previsões de vendas e a concentrar-se em seu outro medicamento, petrelintide, que pode oferecer melhores perspectivas no mercado de obesidade.

Analistas do JPMorgan Destacam Reabertura do Mercado de IPOs em Biotecnologia em Meio à Atividade Contínua de Fusões e Aquisições da Big Pharma

06/15/2026, 10:36 PM business review Analysts: analysts, JPMorgan biotech healthcare

O setor de biotecnologia está passando por um ressurgimento na atividade do mercado público, mas muitas empresas líderes podem preferir a aquisição por grandes empresas farmacêuticas em vez de buscar ofertas públicas iniciais (IPOs). Essa tendência reflete um clima de investimento seletivo e uma mudança estratégica na forma como as empresas de biotecnologia abordam o crescimento e o financiamento.

Biotech M&A Set for Strongest Year Since Pre-Pandemic as Deal Value Reaches $106 Billion in 2026

06/03/2026, 11:30 PM business review biotech healthcare

The biopharma sector is experiencing a significant surge in mergers and acquisitions, with 2026 poised to become the strongest year since before the pandemic, driven by patent expirations and a favorable market environment.

Abivax (ABVX) Shares Plunge Over 30% Following Update on Bowel Disease Drug Trial

06/02/2026, 12:31 AM stock_drop biotech

Abivax is strategically planning to raise funds following the release of crucial trial data, indicating its intent to remain independent amid ongoing takeover speculation, which has significantly influenced its stock performance.

Innovent Biologics (1801.HK) Shares Surge 10% Following $10.5 Billion Partnership with Pfizer

05/28/2026, 08:32 PM announcement biotech

Innovent Biologics has entered a strategic partnership with Pfizer, which is expected to enhance its oncology drug development capabilities.

Analysts BTIG initiate coverage of Absci Corporation (ABSI) with a buy rating and $9 price target, citing potential for ABS-201 in hair loss treatment

05/28/2026, 07:33 AM investing rating_growth Analysts: analysts, BTIG biotech

Absci Corporation's innovative hair loss treatment, ABS-201, has garnered a buy rating from BTIG, with a projected peak sales potential of $2.2 billion, indicating significant market opportunity in a largely underserved sector.

Analysts Goldman Sachs initiate coverage of Hemab Therapeutics (HEMA) with Buy rating and $36 target price, citing potential for unique bleeding disorder treatment

05/26/2026, 07:32 AM investing rating_growth Analysts: analysts, Goldman Sachs biotech

Hemab Therapeutics is positioned for significant growth following its IPO, driven by its development of unique treatments for rare bleeding disorders, as highlighted by Goldman Sachs' bullish outlook.

U.S. Promotes AI Technology in Asia Following Trump-Xi Meeting

05/22/2026, 05:34 AM business announcement ai biotech

The U.S. is intensifying efforts to promote American technology, particularly in artificial intelligence, in Asia amid competition with China, which is developing its own alternatives. This strategic push follows a recent meeting between Presidents Trump and Xi, highlighting the importance of U.S. tech in the region.

Biotech and Real Estate Sectors Show Mixed Performance Ahead of Key Oncology Meeting

05/21/2026, 04:32 PM investing review biotech real_estate

The upcoming meeting of the American Society of Clinical Oncology is poised to influence biotech stocks, which have shown significant gains over the past year despite recent fluctuations. Additionally, a substantial government investment in quantum computing has sparked notable stock increases in that sector.

Topic: biotech